|Market Size||2030: USD 1027.04 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, By Formulation, By Severity and By Application|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Johnson & Johnson, Anika Therapeutics, Atrium Medical Corporation (A Part of Getinge Group), Baxter International, Betatech Medical, C. R. Bard, FzioMed, Innocoll Holdings, Integra LifeSciences Holdings Corporation, MAST Biosurgery, Normedi Nordic, and Sanofi|
|Key Market Opportunities||Increasing surgical procedures for small bowel obstruction|
|Key Market Drivers||
Adhesion barrier is a medical implant used for patients enduring abdominal or pelvic laparotomy as an adjunct intended to lessen the occurrence of postoperative adhesions between the abdominal wall and the under-lying viscera.
Adhesion Barrier Market is expected to record a CAGR of 7.22%.
2020 to 2030 is the growth period calculated for the Adhesion Barrier Market’s growth.
The Adhesion Barrier Market is expected to grow at a steady growth rate due to rising surgical procedures for small bowel obstruction, chronic pelvic pain, infertility, and cost-effective prevention of adhesions among others.
The market challenges faced by Global Adhesion Barrier Market are the risk of using adhesion barriers in patients with a history of hypersensitivity.
MAST Biosurgery, Integra LifeSciences Holdings Corporation, Normedi Nordic, Sanofi, and more have been investing in the market’s growth immensely.